The National Medical Products Administration of China has approved Eli Lilly and Co's Alzheimer's disease therapy, Leqembi (donanemab injection, administered via intravenous infusion once every four weeks) for the treatment of mild cognitive impairment due to Alzheimer's disease and mild dementia. Leqembi is the only therapy with evidence supporting the cessation of treatment after the clearance of amyloid plaques, which may help reduce the treatment burden for patients by decreasing the frequency of infusions and the cost of therapy. Following the USA, Japan, and the United Kingdom, China is another major market that has approved Leqembi for commercialization.